Days
Hours
Minutes
Seconds
-40%
on all our subscriptions*
limited-time offer
Enjoy this offer
* See conditions on site
Capitalization 98.35B 148B 7,515B P/E ratio 2025 *
31.5x
P/E ratio 2026 * 27x
Enterprise value 108B 162B 8,233B EV / Sales 2025 *
6.83x
EV / Sales 2026 * 6.28x
Free-Float
99.87%
Yield 2025 *
1.47%
Yield 2026 * 1.66%
More valuation ratios * Estimated data
Dynamic Chart
1 day-0.46%
1 week-1.74%
Current month-2.20%
1 month-2.63%
3 months+4.93%
6 months+6.83%
Current year+4.80%
More quotes
1 week
298.10
Extreme 298.1
307.10
1 month
291.47
Extreme 291.465
311.38
Current year
265.14
Extreme 265.14
313.55
1 year
228.65
Extreme 228.65
313.55
3 years
228.65
Extreme 228.65
319.78
5 years
227.26
Extreme 227.26
342.75
10 years
71.04
Extreme 71.04
342.75
More quotes
Director TitleAgeSince
Chief Executive Officer 58 31/05/19
Director of Finance/CFO 59 30/09/20
Chief Tech/Sci/R&D Officer 62 30/09/20
Manager TitleAgeSince
Director/Board Member 70 31/03/97
Director/Board Member 68 13/08/13
Director/Board Member 66 15/02/16
More insiders
Add to a list
Change 5d. change 1-year change 3-years change Capi. ($)
-0.46%-1.74%+11.86%-1.67%98.35B
+3.21%-1.53%+33.29%+3.65%51.57B
+0.59%-1.74%+95.77%+74.09%33.79B
-0.49%-1.93%-22.46%-37.55%29.25B
-1.22%-7.82%-6.77%+9.62%16.01B
-1.08%-3.55%+41.94%-26.09%12.25B
-1.95%-5.64%+584.87%+346.48%12.01B
-2.70%-6.70%-4.25%-17.28%11.8B
+2.96%+0.06%+42.47%+30.36%10.27B
-3.24%-1.53%+9.01%-31.56%9.02B
Average -0.32%-3.26%+78.57%+35.01% 28.43B
Weighted average by Cap. +0.26%-2.04%+46.98%+18.46%
See all sector performances

Financials

2025 *2026 *
Net sales 15.78B 23.72B 1,206B 16.91B 25.42B 1,292B
Net income 3.11B 4.68B 238B 3.63B 5.46B 277B
Net Debt 9.39B 14.11B 717B 7.89B 11.86B 603B
More financial data * Estimated data
Logo CSL Limited
CSL Limited is an Australia-based biotechnology company. The Company’s areas of focus include rare and serious diseases, influenza vaccines and iron deficiency and nephrology. The Company’s segments include CSL Behring, CSL Seqirus and CSL Vifor. The CSL Behring segment manufactures, markets and distributes plasma products, gene therapies and recombinants. The CSL Seqirus segment manufactures, markets and distributes predominantly influenza related products and provides pandemic services to governments. The CSL Vifor segment manufactures, markets and distributes products in the therapeutic areas of iron deficiency and nephrology. Its CSL Plasma operates plasma collection networks, with more than 325 plasma collection centers in the United States, Europe and China. The Company operates in Australia, the United States, Germany, the United Kingdom, Switzerland and China. Its products include Respreeza, Zemaira, HAEGARDA, KCENTRA, Hepatitis B, Evogam and others.
Employees
32,698
Calendar
Related indices
More about the company
Date Price Change Volume
09/09/24 300.41 $ -0.46% 571,485
06/09/24 303.99 $ +0.29% 515,094
05/09/24 303.10 $ -0.29% 743,421
04/09/24 303.99 $ -0.67% 537,848
03/09/24 306.03 $ +0.09% 477,231

Delayed Quote Australian S.E., September 09, 2024 at 07:10 am

More quotes
Trading Rating
Investor Rating
ESG Refinitiv
A-
More Ratings
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
15
Last Close Price
203.17USD
Average target price
210.45USD
Spread / Average Target
+3.58%
Consensus

Quarterly revenue - Rate of surprise

-40% Limited Time Offer: Our subscriptions help you unlock hidden opportunities.
BENEFIT NOW